Brief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
09/10/2026 14:03
BRIEF-Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors Oct 9 (Reuters) - HCW Biologics Inc HCWB.O:
HCW BIOLOGICS MAINTAINS MOMENTUM TOWARD COMPLETION OF IND APPLICATION FOR CLINICAL STUDY TO EVALUATE LEAD T-CELL ENGAGER IN SOLID TUMORS
HCW BIOLOGICS - IND APPLICATION ON TRACK TO BE FILED IN 1H 2027
Source text: ID:nGNX8BWTrk
Further company coverage: HCWB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hcw Biologics
See all newsBrief: Hcw Biologics Maintains Momentum Toward Completion Of Ind Application For Clinical Study To Evaluate Lead T-Cell Engager In Solid Tumors
Brief: HCW Biologics Registers Resale Of Up To 1.81 Mln Shares Of Common Stock By Selling Stockholder- SEC Filing
NASDAQ RESUMED AT 10:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:29 AM
NASDAQ RESUMED AT 10:29 AM